A selective cytopheretic inhibitory device for use during cardiopulmonary bypass surgery

201221 citationsJournal Article

Authors

These results suggest that SCD-C therapy may disrupt the systemic leukocyte response during CPB, leading to improved outcomes for CPB-mediated MOD.

Good health and well-being

Published in: Perfusion

Volume 27, Issue 4, pp. 311-319

Field-Weighted Citation Impact: 0.40